India, Feb. 5 -- Shares of Pasithea Therapeutics Corp. (KTTA) surged over 47% on Wednesday morning after the clinical-stage biotechnology company announced a positive Safety Review Committee recommendation from its ongoing phase 1 trial of PAS-004 in advanced cancer.
KTTA is currently trading at $3.1600, up $1.0200 or 47.67%, on an average volume of 50 million shares, above average volume of 44 thousand, on the Nasdaq. The stock opened its trading at $3.6300 after closing at $2.1400. The stock has traded between $2.0400 and $9.2500 in the past 52-week period.
Pasithea Therapeutics announced that the external Safety Review Committee recommended that the company's Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to cohort...